A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
NCT05139017Phase 2/3Recruiting
- Lead sponsor
- Merck Sharp & Dohme LLC (Industry)
- Enrollment
- 290 (estimated)
- Start date
- 14 Jan 2022
- Primary completion
- 24 Sep 2027 (estimated)
- Study completion
- 24 Sep 2027
- Last update posted
- 21 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Sequential
- Masking
- None
- Arms
- 6
Interventions
- Zilovertamab vedotin Biological
- Rituximab Biological
- Gemcitabine Drug
- Oxaliplatin Drug
- Bendamustine Drug
- Granulocyte Colony-Stimulating Factor (G-CSF) Drug
Conditions and primary outcome
- DLBCL
- Diffuse Large B-Cell Lymphoma
Primary outcome
Number of participants who experienced dose-limiting toxicities (DLTs) in Part 1 (Up to ~6 weeks); Number of participants who experienced an adverse event (AE) (Up to ~68 months); Number of participants who discontinued study treatment due to an AE (Up to ~68 months); Overall survival (OS) (Up to ~35 months); Progression-free survival (PFS) (Up to ~35 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT05139017.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05139017 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.